# Skeptic review of merged-conclusion.md

Reviewer: ir-skeptic (session). Date: 2026-10-18. Target: `ir-team/merged-conclusion.md` (written by the main session, not by an analyst). Coverage and reimbursement out of scope. I did not edit the target.

## 0. What I read and checked

**Read in full:**
- the four new-role reports: Set A and Set B clinical chemist, Set A and Set B evidence searcher (Set A searcher lines 1-300 of 533, with the appendix log only grepped; Set B searcher lines 1-215 of ~410, same);
- both skeptic reviews of those four reports (`ir-skeptic-new-roles.md`, `subagents/ir-skeptic-new-roles.md`);
- `subagents/ir-skeptic.md` (lines 20-60), `ir-skeptic.md` (verdict section), `subagents/ir-skeptic-session-review.md` (lines 14-62), `comparison.md` §4.

**Grepped, not read end to end:** the other analyst reports (endocrinologist, scientist, PCP, biostatistician, both sets) and the remaining skeptic text. I looked for each number in the merged file and checked its source. Merged claims that come only from the Set A/B endocrinologist, PCP or scientist reports (for example the Wagner 2021 critique and the clamp/HOMA physiology) I traced to the skeptic text that makes them, not to the analyst reports, so those are second-hand.

**Primary sources I re-checked myself (PubMed abstract unless noted):**
- IRIS NEJM 2016 (PMC full text, via efetch): 9.0% vs 11.8% at 4.8 years, HR 0.76, HOMA-IR >3.0 central entry criterion, 13 prespecified subgroups with "P = 0.94 after adjustment for multiple comparisons". I did not confirm that HOMA-IR is one of the 13.
- Spence 2019 (PMID 30734043), PLIS (34531293), Hu 2024 (38191206), Liu 2026 (42569452), NHANES Xu 2026 (42702103), ODYSSEY sdLDL (42291078).
- LAMP post hoc (42145088): full text via PMC.

**Arithmetic I recomputed:**
- Log-normal RCV at CVI 26.7%: +107% / -52%. Matches the merged file.
- Cutoff-crossing probabilities: 20% above cutoff gives 24%, 1.5x gives 6.1%, 2x gives 0.4%. Matches the merged file.
- IRIS ARR 2.8 points and NNT about 36 (1/0.028 = 35.7). Matches.

**Tools:**
- Scholar Sidekick failed again: `verifyCitation` returned "Too many requests" and `checkRetraction` returned "not subscribed". So identity was checked in PubMed metadata.
- Retraction: Crossref `works/{doi}` (`update-to`/`updated-by`) for 10 DOIs. These were IRIS, Spence, LAMP, PLIS, Liu 2026, EuBIVAS, ARIC, González-González, WHI/Schmiegelow and Marcovina. None carries a retraction, correction or expression-of-concern notice. Hu 2024's lookup crashed on a Unicode title, so Hu is not retraction-checked. This is weaker than Sidekick; it only reflects what Crossref holds.
- I could not re-read the Endocrine Society 2017 pediatric guideline, ADA 2026 §3 or AACE 2022 text (the PMC copies are stubs). Items resting on them are single-source from the searchers, as marked below.

## 1. Ranked problems

### HIGH-1. Guideline coverage is incomplete, and bottom line 3 and the "well supported" list contradict material the searcher reports contain

The file says it takes the four new-role reports "as characterised by the two skeptic reviews" and that it never read them. That is where most omissions come from. Items in the Set A searcher's guideline table (§5.1) or the Set B table (Q4) that the merged file leaves out:

1. **Endocrine Society pediatric obesity guideline 2017 (PMID 28359099), Rec 1.7:** "We recommend against measuring insulin concentrations when evaluating children or adolescents for obesity (1|⊕⊕⊕○)". The Set A searcher gives the rationale as lack of standardised assays, poor reproducibility and a 2.5-fold range of proposed cutoffs. This is the only graded, explicit "recommend against" in the project; the PCOS items are ungraded practice points. Single source: Set B could not retrieve the text (6k-character stub), and neither could I. The abstract has no such sentence. It is a strong, checkable claim, and the merged file should carry it flagged as single-source.
2. **ADA Standards 2026 Rec 3.13 and AACE 2022:** pioglitazone "may be considered" in people with stroke history and "evidence of insulin resistance and prediabetes" (ADA, supporting text cites IRIS HOMA-IR ≥3.0). AACE 2022 says "in persons with insulin resistance, prediabetes or T2D and prior TIA/stroke, pioglitazone should be considered". Two independent retrievals agree (Set A FT-scan; Set B FT-WF for ADA, FT-grep for AACE). Neither names an assay or threshold, so "no guideline requires an IR *measurement*" still holds. But the merged line "No guideline ties IR measurement to a management change" and bottom line 3 ("the only verified IR-threshold niche is the IRIS entry criterion") never say that the IRIS result is already embedded in ADA and AACE wording as an IR-conditioned treatment. A reader would not know the state of the art.
3. **Japan Diabetes Society IR-syndrome criteria 2022 (PMID 35463863):** fasting insulin 30 µU/mL as a major sign for genetic IR syndrome and type B IR (Set A FT-scan). The merged file's own searcher-negatives paragraph mentions this nowhere either. This contradicts bottom line 3, "the only verified IR-threshold niche is the IRIS entry criterion". That sentence is the first-round skeptic's wording, written before the Set A searcher found the JDS document. Fix it, or say why JDS does not count (a severe-syndrome criterion, not an IR screen). A related registered study, NCT07412028 (AP-HP, severe genetic IR within "classic" PCOS), is also not mentioned.
4. **ADA/EASD 2023 precision-medicine consensus (PMID 37794253):** says TyG has "moderate evidence" for CVD prediction (Set A searcher quotation). This is a guideline-type statement that cuts against the file's TyG framing. The merged file relies on Liu 2026 and ATTICA (small or no gain). The two should be set side by side. The consensus statement is about prediction, not reclassification.
5. **Open gap 5 ("Full-text AASLD and ADA recommendation review") is inconsistent with the "well supported" section.** The same file lists AASLD 2023 and ADA 2025 sections as "full text searched" and then lists their review as an open gap. Neither is right as stated. The accurate position is:
   - Set A scanned the full texts of 16 documents by regular expression (AASLD 2023; ADA 2026 §2, 3, 4, 8, 10, 14; ADA 2025 §2; others).
   - Set B scanned only the first 100k characters of ADA 2026 §2, §3 and §10 (of 159k, 275k and 373k).
   - "No recommendation found" is therefore regex- or window-limited, not read. Fix the gap wording and add this caveat to the ADA/AASLD bullets.
6. **"ADA Standards 2025 (sections 2 and 3 searched)"** is correct for Set B's skeptic, who read 2025 and reports 3.12-3.14 as weight, CV risk and pharmacotherapy. Set A scanned 2026. The merged file mixes the two years without saying so.

### HIGH-2. "Registered, no results ... The registry IDs checked out" is overstated, and the five IDs are not one kind of trial

- Set B's skeptic independently confirmed only NCT07710274 and NCT06856291 (and NCT07618663, not used). It states that CTRI, IRCT, ISRCTN and ChiCTR records were "not verifiable by me". The Set A skeptic read the ISRCTN11215387 XML and found oddities (see HIGH-3). So for CTRI/2026/09/117733, IRCT20170812035642N11 and ISRCTN74144960, "checked out" means "retrieved by the searcher", not "checked by a skeptic". Reword.
- The five are not alike. The searcher's own rows show:

| ID | What it is | Per searcher |
|---|---|---|
| CTRI/2026/09/117733 | Only registered trial where HOMA-IR >3.8 (men) / >3.46 (women) decides treatment (metformin vs voglibose) | Not yet recruiting |
| IRCT20170812035642N11 | Personalised diet plans by metabolic profile | Recruiting |
| NCT07710274 (PRISM-I) | IR-enriched; HOMA-IR is the primary outcome | Recruiting |
| ISRCTN74144960 (MET-HFpEF) | IR (FIRI ≥2.7) is one of three entry routes, with prediabetes or BMI ≥30 | Recruiting |
| NCT06856291 | Observational | Completed |

  The merged file only flags PRISM-I and NCT06856291. The other three are listed as if they were comparable.
- **Omitted trial that is closer to "IR-guided care" than anything listed:** ISRCTN11215387 ("ITT-IR", Wakayama Rosai Hospital). It is a cluster-randomised open trial of an "intention to treat insulin resistance" policy (self-monitoring, visceral-fat follow-up, diet, non-insulinotropic drugs) against conventional diabetes care. It ran 2016-2021, and no publication was found. The Set A skeptic found the record shows a 3-month recruitment window with 757 final enrolment, unexplained, and that the allocation trigger is not an IR laboratory measurement. It is not evidence of a benefit of testing, but "no randomized trial comparing IR-guided care with usual care was found" should say that this policy trial exists and was unpublished.

### HIGH-3. Randomised evidence that stratifies or tests interaction by IR was largely dropped. It bears directly on the 55-60% "shown not to add value" figure and on open gap 3

The merged file says the closest completed trials are IRIS, PLIS and "small pilots", and that "IR-stratified therapy evidence ... no run closed" (gap 3). The Set A and Set B searchers list the following:

| Item | What it is | Result |
|---|---|---|
| DIETFITS, Gardner 2018 (PMID 29466592) | n=609; prespecified diet × INS-30 interaction | **P = 0.47**, null |
| Gardner 2016 pilot (26638192) | n=61; diet within IR strata | no interaction |
| Cornier 2005 (15897479) | n=21 | weight loss favoured the diet matched to IR state |
| 2025 Obesity RCT (39756404) | n=69 | low-carb advantage in the low-SI subgroup |
| PERSON, Trouwborst 2023 Cell Metab (36599304; NCT03708419) | n=242; RCT of OGTT-derived muscle-IR vs liver-IR phenotype-matched vs mismatched diet | Set A read the abstract only and reported no result |
| Nat Metab 2024 (38177805) | semaglutide vs dapagliflozin in SIRD/SIDD | no significant drug × subgroup interaction (abstract) |
| LIRA-ADD2SGLT2i post hoc (34132018) | HOMA-IR tertiles | no significant interaction (P >0.05) |
| GRADE, Utzschneider (38190619) | HOMA2-%S | heterogeneity P=0.009 for initial HbA1c reduction on sitagliptin vs the other arms |
| DPP k-means (40497454) | post hoc clusters | metformin benefit greater in a "severe IR with severe obesity" cluster (P interaction <0.05); a clinical-variable model discriminated risk better than the clusters |
| PCOS IPD meta-analysis (31647106) | baseline insulin | interaction for clomiphene+metformin vs clomiphene, live birth RR 1.03 (1.01-1.06) |

- Most are abstract-level and weight-loss or glycaemic outcomes, not hard outcomes. The point is that the merged file's "not shown" evidence base is thinner than the facts available: the only prespecified, adequately sized interaction test (DIETFITS, n=609) is null, and nothing is cited for it.
- Line 46 ("no one found a trial of IR-stratified metformin") is true for stratified trials, but the PCOS IPD interaction (RR 1.03) and the DPP cluster result are evidence that bear on it.
- I read these only through the searchers' tables (which are abstract-based for most rows). I did not re-read the abstracts myself except for the LAMP, PLIS and IRIS items.

### HIGH-4. The confidence figures are not a computed quantity. As written they are the upper end of the skeptic range, and the sources and scope are blurred

- 85% for bottom line 1: it comes from the Set B subagent skeptic and the Set B session-review skeptic (both ~85%), whose search was "targeted rather than systematic" by its own words. The Set A first-round skeptic gave ~80% (and 40-50% for "shown not to add value"). The two new-roles skeptics gave ~80% for the chemist's and searcher's central conclusions, which is a different statement. The merged file says "Skeptic confidence" without naming whom or giving the lower figures.
- 55-60% for bottom line 2: this is the session-review skeptic's figure for "shown not to add value". The identical number appears in line 42 for something else (the completeness of the searcher's negative list, from both new-roles skeptics: 55% and 55-60%). The file attributes the same number to two different quantities.
- My view of what is justified:
  - **Bottom line 1** ("no established clinical utility today for routine measurement") is justified at about 80-85%, as long as it stays scoped to routine measurement. None of the omissions above overturn it. But the merged file should state that this is a judgement of how likely the verdict is to survive further checking, not a measurement, and that it predates the Set A guideline findings.
  - **Bottom line 2** is justified at 50-60%, probably nearer 50%. The prespecified DIETFITS null (HIGH-3) and the incremental-value nulls (WHI, Hu, NHANES, Liu 2026) are the nearest to "shown not to", but none is a decision-curve or an adequately powered, outcome-based test.
  - **Bottom line 3** needs rewording (HIGH-1 items 2 and 3).

### MEDIUM-5. Update section vs the chemist reports: mostly accurate, with one overreach, one misattribution, and several omissions

I read the four reports. The section's numbers match:
- EuBIVAS 26.7%, ARIC 30.4%, QUICKI 4.1%.
- The -298 to +303 pmol/L range (PMID 40802520).
- The 1.7-23.2% relative SD (Rosli, PMID 35622611).
- The RCV and misclassification numbers (recomputed above).
- The "not established" items on the reference procedure and on LC-MS/MS vs immunoassay.

Problems:

1. **"The old 'about 25% inter-laboratory CV' is a ceiling from older kits."** This is not supported. Both chemist reports cite Zhou 2022 (PMID 35177563, 94 Chinese laboratories, recent): inter-laboratory CV 21.8% and inter-system CV 22.4% for insulin. The merged file omits it. Rosli's upper bound (23.2%) is also close to 25%. The defensible wording is "about 2-25% depending on which kit set, with no evidence that current platforms are better, and three recent-to-old studies landing at 22-25% for insulin". The three sources measure different quantities, which the merged file does say.
2. **"The symmetric 70-80% figure in one chemist report is too tight."** It is correct as a statement about the symmetric formula, but the attribution is unfair. Set A's chemist already wrote "log-normal asymmetric form would be roughly +100% / -50%". Set B's chemist wrote that the RCV "is asymmetric" and cited +90/-47% from Jayagopal, and the Set B skeptic did the +107/-52 correction. Say "Set B chemist applied the symmetric figure".
3. **Isokuortti "HOMA-IR 2.0 in Helsinki reads 1.3-2.1 elsewhere".** The Set A skeptic checked this against the abstract. It is not about one patient. The merged file does not cite it, so no error here, but the chemist headline stays uncorrected and the omission matters because it is the most vivid number.
4. **Omitted chemist findings that change a downstream use:**
   - HOMA-IR cutoff portability is shown directly by the Gutenberg Health Study (PMID 34380182): a 97.5th percentile of 2.35 for one assay, with a three-assay substudy showing systematic differences. Set B's skeptic lists it as surviving scrutiny.
   - Manley 2008 (PMID 18535197, Set B searcher full-text): HOMA-IR ranges 0.8-2.0 (normoglycaemia), 1.9-3.2 (prediabetes), 1.5-2.9 (T2D) across 11 assays. This is the only HOMA-IR-specific cross-assay range in the project; the merged file names "Manley 2007/2008" in line 20 but gives no figure.
   - C-peptide is better standardised than insulin: after recalibration the inter-system CV fell 24.5% to 5.7% (Zhou, verified by the Set A skeptic against the abstract), but its CVI is also about 24% (n=12, young, RIA era). The Set A skeptic noted that Set B's "no advantage" rests on n=12. The merged file mentions C-peptide only as a diagnostic role.
   - Insulin therapy and analogue cross-reactivity make insulin and C-peptide-based indices uninterpretable (Set B chemist; LAMP also excluded patients on insulin).
   - The chemist's "MDC 2.3 > most cutoffs (1.9-2.7)" is mentioned in line 20 as "MDC 2.3" but not with its comparison; the Set A skeptic called that comparison rhetorical, so leaving it out is defensible.
5. **Line 30: "a fixed cutoff cannot be stable" overstates it** is correct and is the Set B skeptic's correction. OK.

### MEDIUM-6. Wording stronger or weaker than the sources

1. **Hu 2024 (line 18): "HOMA-IR added little to BMI plus HbA1c."** The base model also includes age, sex, smoking, dyslipidaemia and hypertension. The abstract says adding HOMA-IR and HOMA-β "did not further materially improve" it, while adding fasting glucose raised AUC 0.79 to 0.84 (cNRI 0.61, IDI 0.09). Set A's full-text scan reports NRI 0.13 (0.05-0.22) and IDI 0.04 (0.03-0.05) for model 3 versus model 1. That is a statistically significant but small gain, not zero. The accurate wording is "adds much less than fasting glucose does and nothing beyond it (model 4 = model 2)". I confirmed the abstract; the model-3 NRI/IDI come from the searcher's full-text scan and I did not re-verify them.
2. **NHANES (PMID 42702103, line 18):** the outcome is cardiovascular and cerebrovascular **mortality**, not incident disease. The abstract also reports that, under competing risks, higher HOMA-IR had a *lower* subdistribution hazard and a J-shaped pattern. The merged file says only "neither improved discrimination". Add the outcome type.
3. **IRIS (line 21):** the merged file omits two points that weaken IRIS as evidence that the HOMA-IR *value* matters:
   - There were 13 prespecified subgroups with no significant heterogeneity (multiplicity-adjusted P = 0.94, my reading of the figure legend). The Set B skeptic says HOMA-IR was among the subgroup variables; I could not confirm that.
   - Spence 2019 is titled "A Post Hoc Analysis of the IRIS Randomized Clinical Trial", and its abstract says the glucose, HbA1c and adherence subgroups were prespecified in the analysis plan. The merged file says only "prespecified". The HR 0.70 (0.56-0.88) ITT figure is correct. Give both.
4. **LAMP (line 38):** accurate on interaction P 0.02, post hoc, no multiplicity adjustment, 3 months, early termination (loss of funding), overall HR 0.48. Corrections and additions:
   - "complete-case (510 of 636)" understates the selection. Of 636, 114 were excluded for insulin use in the week before onset, and 12 more for missing glucose or insulin. So most of the exclusion is a clinical selection (insulin users), not a missing-data issue.
   - In the non-IR group the point estimate favoured control (11.5% vs 9.5%; HR 1.22, 0.47-3.16).
   - The control-arm event rate was 18.1% in IR versus 9.5% in non-IR, so the interaction is partly a prognostic imbalance.
   - The continuous spline interaction was P = 0.07 (nonlinear P = 0.02).
   - HOMA-IR used local assays without central standardisation (the paper says so).
   - The ARR of 12.3 points (NNT 8) is crude and from a post hoc subgroup, and should not be quoted without those caveats. The merged file does not quote it, which is good.
5. **Barzegar 2020 (line 39), "only age under 60":** the abstract reads "aged <60", n=6175 of 7521. The searcher flagged the garbled table header. Fine as written.
6. **ODYSSEY OUTCOMES (line 38):** the merged file says it "reports findings by degree of insulin resistance". The abstract says the sdLDL-C/LDL-C/MACE relationships were "similar in patients with greater or lesser degrees of insulin resistance", and the treatment HR did not vary across LDL-C or sdLDL-C. It is not a treatment × IR test. The merged file's caution is fine; add that the stated finding is "similar", so if anything it leans to no IR modification.
7. **Line 22 ("HOMA-IR versus clamp category agreement kappa 0.63")** is listed under "Surrogates are modest" with no mention that the same paper reports r = -0.82 and that the authors called agreement good. The merged file does correct the biostatistician's gloss in "Corrections". Keep it as is, but add r.
8. **Line 19:** González-González 2022 (PMID 36181637) also found *no* association of HOMA-IR with fatal MACE (Set B skeptic). The merged file lists only the positive outcomes.
9. **"EASL MASLD PMIDs 38851997, 38852583 and 38869512 are the same guideline in three journals" (line 56):** 38869512 is the Diabetologia executive summary. The Set B session skeptic called it "two journals". Say "full guideline in two journals plus an executive summary".

### MEDIUM-7. "Not found" claims in the file are mostly handled well. Three need tightening

- **"No randomized trial comparing IR-guided care with usual care was found"** (line 36). The skeptics rate this one as the best supported negative; I agree, with the ISRCTN11215387 addition above.
- **Searcher negatives paragraph (line 42):** accurate. I would add that the Set B skeptic demonstrated that the S100 string (statin/PCSK9/colchicine with baseline HOMA-IR or TyG: "0 hits") could not have returned anything because it was a six-way conjunction, and that a simpler string found 13 records including ODYSSEY. Also, the Set B skeptic found the 246-record reclassification string unscreened. The merged file mentions "strings that were too narrow or broken", which covers this.
- **Gap 0** lists the searches to run. I would add one the searchers did not run and no skeptic ran: a **MeSH-based** PubMed search (Insulin Resistance[Majr] with Randomized Controlled Trial[pt] plus precision-medicine/patient-selection terms). The Set B skeptic listed it as missing.

### LOW-8. Smaller points

- **Provenance line:** "about 70 PMIDs (Set A) and about 75-85 (Set B, two independent reviewers)": I cannot verify the counts. The Set B new-roles skeptic reports about 28 + 33 identifiers and 22 DOIs; the session skeptic 28 DOIs. Fine as an order of magnitude. "No fabricated citations or retractions" matches every skeptic file I read, and my own spot-check (10 DOIs in Crossref; PMID identities for the six items above) found none.
- **Line 3:** "five skeptic reviews" includes the two new-roles reviews; fine.
- **PLIS:** the merged file says 1,105 people (the publication); the registry record says 1145 actual (Set A). Not an error, but not reconciled.
- **"Added by the evidence-searcher and clinical-chemist runs" header:** the update note on line 4 still says "I have not read the four reports themselves". After this review that is no longer true of a reader of this file. If the main session adopts these corrections it should update the note.
- **Line 67 ("Prefer Set A for the biostatistician role"):** matches comparison.md §4 and the session skeptic's verdict. It omits that Set A's biostatistician contributes Framingham Offspring (PMID 17533210: AROC 0.85 to 0.850-0.854 when HOMA-IR, insulin or Gutt ISI was added) and Wang 2022 (PMID 35700159: per-SD HR 1.04 in normal glucose tolerance, 1.15 in diabetes), both incremental-value nulls the merged file never cites. Note a conflict: the Set A searcher lists 17533210 as "not verified whether insulin was included"; the Set A biostatistician states AROC figures for it. Someone should check.

## 2. Inconsistencies inside the merged file

1. Bottom line 3 says the only verified IR-threshold niche is IRIS. The searcher reports a second (JDS fasting insulin 30 µU/mL). The first-round wording was carried forward without re-checking.
2. Lines 16-17 ("full text searched") vs open gap 5 ("Full-text AASLD and ADA review"). They cannot both be right.
3. Line 20 says only one small study gives an inter-laboratory HOMA-IR CV of 25% and "do not cite four sources". Line 28 then says "the old 'about 25% inter-laboratory CV' is a ceiling from older kits". The first sentence is about HOMA-IR; the second is about insulin and treats the 25% as a general ceiling. Use one framing.
4. Line 8 and line 42 attach the same "55-60%" to different quantities.
5. Line 40 says ESC, AHA 2023, AACE 2026, NICE, KDIGO and ISPAD could not be read in full. Set A's own list of unread documents is ESC 2021, AHA 2023, AACE 2026, ADA/EASD 2026 T2D consensus and the 2018 cholesterol guideline; NICE, KDIGO and ISPAD come from Set B. Both lists should be combined (the merged file omits the ADA/EASD 2026 consensus and the 2018 cholesterol guideline).

## 3. What survived

- The PCOS 2023 wording (practice points 1.9.12 and 3.1.10) and its caveats: consensus, assay-inaccuracy rationale, not proof of no benefit. Read in full text by both Set A and Set B skeptics.
- The EASL MASLD permissive recommendation ("may be considered", LoE 3, weak, 92% agreement) and the correction of "IR is not in the MASLD guideline". Read in full text by the Set B skeptic and the Set A and B searchers.
- IRIS numbers: 9.0% vs 11.8%, HR 0.76, entry HOMA-IR >3.0, central-lab caveat, NNT about 36 (my recomputation). Its limits as stated: no non-IR comparator; assay-bound threshold.
- LAMP numbers and the post hoc, early-termination and multiplicity caveats (re-read in full text).
- Liu 2026: C-index 0.731 to 0.732 (P=0.559), pooled 0.0004 (-0.0092 to 0.0100), 0.0051 (0.0007-0.0094) without Barzegar, very low GRADE; TyG quartiles improved IDI/NRI. All verified in the abstract.
- Within-person variation figures and the RCV and cutoff-crossing arithmetic. Assay disagreement (−298 to +303 pmol/L; 1.7-23.2% relative SD).
- The corrections list (San Antonio vs IRAS, the Schmidt 2005 point, the kappa gloss, the AUC 0.86 range) matches the skeptic files.
- The statement that nothing in the file's PMIDs and DOIs I checked is fabricated or retracted (limits in §0).

## 4. Verdict on the bottom line and confidence figures

- **Bottom line 1** ("no established clinical utility today for routine IR measurement") is justified at about 80-85%, scoped to *routine* measurement. Nothing I found overturns it; the Set A guideline items (ADA 3.13, AACE 2022, JDS, Endocrine Society Rec 1.7) refine rather than reverse it. The 85% is a judgement, taken from the more confident Set B skeptics, that predates these items. I would say "about 80-85%" and name the source.
- **Bottom line 2** is not justified at the top of 55-60%; I would give 50-55%, and word it "not shown, with one prespecified null interaction test (DIETFITS) and several small incremental-value nulls".
- **Bottom line 3** is internally inconsistent and needs rewording: IRIS is no longer the only threshold niche (JDS), and IRIS is already used in ADA and AACE wording.
- **The file is more cautious and more accurate than the first merge**, and the honest provenance note helps. Its main weakness is the one it names: the four new reports were taken from skeptic summaries, so everything the skeptics did not discuss (DIETFITS, PERSON, ITT-IR, Endocrine Society, ADA 3.13, JDS, Gutenberg, Manley 2008, Zhou 2022) is missing.

## 5. What would fix it

1. Add the guideline items in HIGH-1 and reconcile bottom line 3.
2. Add the IR-stratified and interaction table in HIGH-3 (marked abstract-level) and change gap 3 accordingly.
3. Replace "registry IDs checked out" with the actual check status and describe each registry type.
4. Name the source and scope of each confidence figure; lower bottom line 2.
5. Replace "ceiling from older kits" with the range and add Zhou 2022 and Manley 2008.
6. Re-read, or have a teammate verify, the Endocrine Society 2017 Rec 1.7 and PERSON's primary result from full text, since both are single-source here.
